CLEAR-DE study to assess topical therapy for non-proliferative diabetic retinopathy

CHMP recommends authorization for LP.8.1-targeting vaccine ahead of 2025-2026 season

Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in […]

Collaboration aims to advance next-generation therapeutics and vaccines

First patient dosed in phase 1b/2a study of procizumab

Irish biotech’s germ-free egg platform could help close global shortfall

GlueSEEKER enables rational design of targeted protein degraders

Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients

EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics

First patient dosed in BUOY-1 study targeting MDD with or without anxious distress